US9260723B2ActiveUtilityPatentIndex 99
RNA-guided human genome engineering
Est. expiryDec 17, 2032(~6.5 yrs left)· nominal 20-yr term from priority
C12N 15/63C12N 15/90C12N 9/22C12N 2310/20C12N 2800/80C12N 2810/55C12Y 301/00C12N 15/10C12N 15/102C12N 15/87C12N 15/1024C12N 15/907C12N 15/85C12N 15/01C12N 15/8201C12N 15/81C12N 15/79C12N 15/113C12N 15/11C12N 5/10A61K 48/00
99
PatentIndex Score
144
Cited by
58
References
9
Claims
Abstract
A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A method of integrating foreign DNA into a genomic nucleic acid sequence of a eukaryotic cell comprising providing to the eukaryotic cell a single stranded DNA (ssDNA) donor sequence tethered to a guide RNA sequence via hybridization, wherein the guide RNA sequence comprises a spacer sequence complementary to a target nucleic acid sequence, providing to the eukaryotic cell a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target nucleic acid sequence in a site specific manner, wherein the spacer sequence of the guide RNA sequence binds to the complementary target nucleic acid sequence and the Cas9 enzyme cleaves the target nucleic acid sequence in a site specific manner; and wherein the ssDNA donor sequence is integrated into the genomic nucleic acid sequence.
2. The method of claim 1 wherein the ssDNA donor nucleic acid is integrated into the genomic nucleic acid sequence by homologous recombination.
3. The method of claim 1 wherein the guide RNA sequence is provided to the cell by introducing to the cell a nucleic acid encoding the guide RNA sequence, wherein the Cas9 enzyme is provided to the cell by introducing to the cell a nucleic acid encoding the Cas9 enzyme, and wherein the cell expresses the guide RNA and the Cas9 protein.
4. The method of claim 1 wherein the eukaryotic cell is a mammalian cell.
5. The method of claim 1 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
6. The method or claim 1 wherein the eukaryotic cell is a human cell.
7. The method of claim 1 wherein the guide RNA sequence is between about 10 to about 250 nucleotides.
8. The method of claim 1 wherein the guide RNA sequence is between about 20 to about 100 nucleotides.
9. The method of claim 1 wherein the guide RNA sequence is between about 100 to about 250 nucleotides.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.